APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preclinical Assets

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Preclinical Assets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

16 January 2026196 pages

Choose your research edition.

Industry ResearchPreclinical Assets Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Preclinical Assets Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Preclinical Assets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preclinical Assets Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Preclinical Assets Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Preclinical Assets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Preclinical Assets include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Preclinical Assets market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Preclinical Assets and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Preclinical Assets revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Preclinical Assets market size, projected growth trends, production technologies, key applications, and end-use industries.

Preclinical Assets Segment by Company

Eurofins Scientific

Viroclinics Xplore

SGS

Intertek Group

AmplifyBio

IQVIA

ICON plc

Medpace

Pharmatest Services

PPD

Crown Bioscience

Comparative Biosciences

TCG Lifesciences

Domainex

Absorption Systems

Preclinical Assets Segment by Type

Bioanalysis and DMPK Studies

Toxicology Testing

Compound Management

Safety Pharmacology

Others

Preclinical Assets Segment by Application

Biopharmaceutical Companies

Government Institutes

Research institutes

Others

Preclinical Assets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Assets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preclinical Assets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Assets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Preclinical Assets in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preclinical Assets industry.

Chapter 3: Detailed analysis of Preclinical Assets companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Preclinical Assetsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Preclinical Assets Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Bioanalysis and DMPK Studies Table 3. Key Players of Toxicology Testing Table 4. Key Players of Compound Management Table 3. Key Players of Safety Pharmacology Table 4. Key Players of Others Table 5. Global Preclinical Assets Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Biopharmaceutical Companies Table 7. Key Players of Government Institutes Table 8. Key Players of Research institutes Table 9. Key Players of Others Table 10. Global Preclinical Assets Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Preclinical Assets Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Preclinical Assets Market Share by Region (2021-2026) Table 13. Global Preclinical Assets Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Preclinical Assets Market Share by Region (2027-2032) Table 15. Preclinical Assets Industry Trends Table 16. Preclinical Assets Industry Drivers Table 17. Preclinical Assets Industry Opportunities and Challenges Table 18. Preclinical Assets Industry Restraints Table 19. Global Preclinical Assets Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Preclinical Assets Revenue Market Share by Company (2021-2026) Table 21. Global Preclinical Assets Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Preclinical Assets Key Company Head Office and Area Served Table 23. Global Preclinical Assets Company, Product Type & Application Table 24. Global Preclinical Assets Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Preclinical Assets by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Preclinical Assets Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Preclinical Assets Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Preclinical Assets Revenue Market Share by Type (2021-2026) Table 31. Global Preclinical Assets Revenue Market Share by Type (2027-2032) Table 32. Global Preclinical Assets Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Preclinical Assets Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Preclinical Assets Revenue Market Share by Application (2021-2026) Table 36. Global Preclinical Assets Revenue Market Share by Application (2027-2032) Table 37. Eurofins Scientific Company Information Table 38. Eurofins Scientific Business Overview Table 39. Eurofins Scientific Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Eurofins Scientific Preclinical Assets Product Portfolio Table 41. Eurofins Scientific Recent Development Table 42. Viroclinics Xplore Company Information Table 43. Viroclinics Xplore Business Overview Table 44. Viroclinics Xplore Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Viroclinics Xplore Preclinical Assets Product Portfolio Table 46. Viroclinics Xplore Recent Development Table 47. SGS Company Information Table 48. SGS Business Overview Table 49. SGS Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. SGS Preclinical Assets Product Portfolio Table 51. SGS Recent Development Table 52. Intertek Group Company Information Table 53. Intertek Group Business Overview Table 54. Intertek Group Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Intertek Group Preclinical Assets Product Portfolio Table 56. Intertek Group Recent Development Table 57. AmplifyBio Company Information Table 58. AmplifyBio Business Overview Table 59. AmplifyBio Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. AmplifyBio Preclinical Assets Product Portfolio Table 61. AmplifyBio Recent Development Table 62. IQVIA Company Information Table 63. IQVIA Business Overview Table 64. IQVIA Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. IQVIA Preclinical Assets Product Portfolio Table 66. IQVIA Recent Development Table 67. ICON plc Company Information Table 68. ICON plc Business Overview Table 69. ICON plc Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. ICON plc Preclinical Assets Product Portfolio Table 71. ICON plc Recent Development Table 72. Medpace Company Information Table 73. Medpace Business Overview Table 74. Medpace Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Medpace Preclinical Assets Product Portfolio Table 76. Medpace Recent Development Table 77. Pharmatest Services Company Information Table 78. Pharmatest Services Business Overview Table 79. Pharmatest Services Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Pharmatest Services Preclinical Assets Product Portfolio Table 81. Pharmatest Services Recent Development Table 82. PPD Company Information Table 83. PPD Business Overview Table 84. PPD Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. PPD Preclinical Assets Product Portfolio Table 86. PPD Recent Development Table 87. Crown Bioscience Company Information Table 88. Crown Bioscience Business Overview Table 89. Crown Bioscience Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Crown Bioscience Preclinical Assets Product Portfolio Table 91. Crown Bioscience Recent Development Table 92. Comparative Biosciences Company Information Table 93. Comparative Biosciences Business Overview Table 94. Comparative Biosciences Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Comparative Biosciences Preclinical Assets Product Portfolio Table 96. Comparative Biosciences Recent Development Table 97. TCG Lifesciences Company Information Table 98. TCG Lifesciences Business Overview Table 99. TCG Lifesciences Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. TCG Lifesciences Preclinical Assets Product Portfolio Table 101. TCG Lifesciences Recent Development Table 102. Domainex Company Information Table 103. Domainex Business Overview Table 104. Domainex Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. Domainex Preclinical Assets Product Portfolio Table 106. Domainex Recent Development Table 107. Absorption Systems Company Information Table 108. Absorption Systems Business Overview Table 109. Absorption Systems Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Absorption Systems Preclinical Assets Product Portfolio Table 111. Absorption Systems Recent Development Table 112. North America Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 113. North America Preclinical Assets Market Size by Type (2027-2032) & (US$ Million) Table 114. North America Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 115. North America Preclinical Assets Market Size by Application (2027-2032) & (US$ Million) Table 116. North America Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America Preclinical Assets Market Size by Country (2021-2026) Table 118. North America Preclinical Assets Market Size by Country (2027-2032) Table 119. Europe Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 120. Europe Preclinical Assets Market Size by Type (2027-2032) & (US$ Million) Table 121. Europe Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 122. Europe Preclinical Assets Market Size by Application (2027-2032) & (US$ Million) Table 123. Europe Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe Preclinical Assets Market Size by Country (2021-2026) Table 125. Europe Preclinical Assets Market Size by Country (2027-2032) Table 126. China Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 127. China Preclinical Assets Market Size by Type (2027-2032) & (US$ Million) Table 128. China Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 129. China Preclinical Assets Market Size by Application (2027-2032) & (US$ Million) Table 130. Asia Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 131. Asia Preclinical Assets Market Size by Type (2027-2032) & (US$ Million) Table 132. Asia Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 133. Asia Preclinical Assets Market Size by Application (2027-2032) & (US$ Million) Table 134. Asia Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Asia Preclinical Assets Market Size by Country (2021-2026) Table 136. Asia Preclinical Assets Market Size by Country (2027-2032) Table 137. South America, Middle East & Africa Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 138. South America, Middle East & Africa Preclinical Assets Market Size by Type (2027-2032) & (US$ Million) Table 139. South America, Middle East & Africa Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 140. South America, Middle East & Africa Preclinical Assets Market Size by Application (2027-2032) & (US$ Million) Table 141. South America, Middle East & Africa Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. South America, Middle East & Africa Preclinical Assets Market Size by Country (2021-2026) Table 143. South America, Middle East & Africa Preclinical Assets Market Size by Country (2027-2032) Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Preclinical Assets Product Image Figure 2. Global Preclinical Assets Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Preclinical Assets Market Share by Type: 2025 VS 2032 Figure 4. Bioanalysis and DMPK Studies Image Figure 5. Toxicology Testing Image Figure 6. Compound Management Image Figure 7. Safety Pharmacology Image Figure 8. Others Image Figure 9. Global Preclinical Assets Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Preclinical Assets Market Share by Application: 2025 VS 2032 Figure 11. Biopharmaceutical Companies Image Figure 12. Government Institutes Image Figure 13. Research institutes Image Figure 14. Others Image Figure 15. Global Preclinical Assets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 17. Global Preclinical Assets Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global Preclinical Assets Market Share by Players in 2025 Figure 20. Global Top 5 and 10 Preclinical Assets Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Preclinical Assets Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Preclinical Assets Revenue Market Share by Type (2021-2032) Figure 24. Global Preclinical Assets Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Preclinical Assets Revenue Market Share by Application (2021-2032) Figure 26. North America Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 27. North America Preclinical Assets Market Share by Type (2021-2032) Figure 28. North America Preclinical Assets Market Share by Application (2021-2032) Figure 29. North America Preclinical Assets Market Share by Country (2021-2032) Figure 30. United States Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 31. Canada Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 32. Mexico Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 33. Europe Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 34. Europe Preclinical Assets Market Share by Type (2021-2032) Figure 35. Europe Preclinical Assets Market Share by Application (2021-2032) Figure 36. Europe Preclinical Assets Market Share by Country (2021-2032) Figure 37. Germany Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 38. France Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 39. U.K. Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 40. Italy Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 41. Russia Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 43. China Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 44. China Preclinical Assets Market Share by Type (2021-2032) Figure 45. China Preclinical Assets Market Share by Application (2021-2032) Figure 46. Asia Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 47. Asia Preclinical Assets Market Share by Type (2021-2032) Figure 48. Asia Preclinical Assets Market Share by Application (2021-2032) Figure 49. Asia Preclinical Assets Market Share by Country (2021-2032) Figure 50. Japan Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 51. South Korea Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 54. India Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 55. Australia Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Preclinical Assets Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa Preclinical Assets Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa Preclinical Assets Market Share by Country (2021-2032) Figure 60. Brazil Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 61. South Africa Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 63. Turkey Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 64. Argentina Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 65. UAE Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 66. Egypt Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 67. Chile Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Compound Management
  • Safety Pharmacology
  • Others
Applications
  • Biopharmaceutical Companies
  • Government Institutes
  • Research institutes
  • Others
Companies covered
  • Eurofins Scientific
  • Viroclinics Xplore
  • SGS
  • Intertek Group
  • AmplifyBio
  • IQVIA
  • ICON plc
  • Medpace
  • Pharmatest Services
  • PPD
  • Crown Bioscience
  • Comparative Biosciences
  • TCG Lifesciences
  • Domainex
  • Absorption Systems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Preclinical Assets Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Bioanalysis and DMPK Studies
  5. 1.2.3 Toxicology Testing
  6. 1.2.4 Compound Management
  7. 1.2.5 Safety Pharmacology
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Preclinical Assets Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Biopharmaceutical Companies
  12. 1.3.3 Government Institutes
  13. 1.3.4 Research institutes
  14. 1.3.5 Others
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global Preclinical Assets Growth Trends by Region
  17. 1.5.1 Global Preclinical Assets Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 Preclinical Assets Market Size by Region (2021-2026)
  19. 1.5.3 Preclinical Assets Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global Preclinical Assets Market Dynamics
  1. 2.1 Preclinical Assets Industry Trends
  2. 2.2 Preclinical Assets Industry Drivers
  3. 2.3 Preclinical Assets Industry Opportunities and Challenges
  4. 2.4 Preclinical Assets Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Preclinical Assets Revenue by Company (2021-2026)
  2. 3.2 Global Preclinical Assets Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Preclinical Assets Key Company Head office and Area Served
  4. 3.4 Global Preclinical Assets Company, Product Type & Application
  5. 3.5 Global Preclinical Assets Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Preclinical Assets Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Preclinical Assets Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Preclinical Assets Tier 1, Tier 2, and Tier 3
4 Preclinical Assets Market by Type
  1. 4.1 Global Preclinical Assets Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Preclinical Assets Market Size by Type (2021-2032)
  3. 4.3 Global Preclinical Assets Market Size Share by Type (2021-2032)
5 Preclinical Assets Market by Application
  1. 5.1 Global Preclinical Assets Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Preclinical Assets Market Size by Application (2021-2032)
  3. 5.3 Global Preclinical Assets Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Eurofins Scientific
  2. 6.1.1 Eurofins Scientific Company Information
  3. 6.1.2 Eurofins Scientific Business Overview
  4. 6.1.3 Eurofins Scientific Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Eurofins Scientific Preclinical Assets Product Portfolio
  6. 6.1.5 Eurofins Scientific Recent Developments
  7. 6.2 Viroclinics Xplore
  8. 6.2.1 Viroclinics Xplore Company Information
  9. 6.2.2 Viroclinics Xplore Business Overview
  10. 6.2.3 Viroclinics Xplore Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Viroclinics Xplore Preclinical Assets Product Portfolio
  12. 6.2.5 Viroclinics Xplore Recent Developments
  13. 6.3 SGS
  14. 6.3.1 SGS Company Information
  15. 6.3.2 SGS Business Overview
  16. 6.3.3 SGS Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 SGS Preclinical Assets Product Portfolio
  18. 6.3.5 SGS Recent Developments
  19. 6.4 Intertek Group
  20. 6.4.1 Intertek Group Company Information
  21. 6.4.2 Intertek Group Business Overview
  22. 6.4.3 Intertek Group Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Intertek Group Preclinical Assets Product Portfolio
  24. 6.4.5 Intertek Group Recent Developments
  25. 6.5 AmplifyBio
  26. 6.5.1 AmplifyBio Company Information
  27. 6.5.2 AmplifyBio Business Overview
  28. 6.5.3 AmplifyBio Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AmplifyBio Preclinical Assets Product Portfolio
  30. 6.5.5 AmplifyBio Recent Developments
  31. 6.6 IQVIA
  32. 6.6.1 IQVIA Company Information
  33. 6.6.2 IQVIA Business Overview
  34. 6.6.3 IQVIA Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 IQVIA Preclinical Assets Product Portfolio
  36. 6.6.5 IQVIA Recent Developments
  37. 6.7 ICON plc
  38. 6.7.1 ICON plc Company Information
  39. 6.7.2 ICON plc Business Overview
  40. 6.7.3 ICON plc Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 ICON plc Preclinical Assets Product Portfolio
  42. 6.7.5 ICON plc Recent Developments
  43. 6.8 Medpace
  44. 6.8.1 Medpace Company Information
  45. 6.8.2 Medpace Business Overview
  46. 6.8.3 Medpace Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Medpace Preclinical Assets Product Portfolio
  48. 6.8.5 Medpace Recent Developments
  49. 6.9 Pharmatest Services
  50. 6.9.1 Pharmatest Services Company Information
  51. 6.9.2 Pharmatest Services Business Overview
  52. 6.9.3 Pharmatest Services Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Pharmatest Services Preclinical Assets Product Portfolio
  54. 6.9.5 Pharmatest Services Recent Developments
  55. 6.10 PPD
  56. 6.10.1 PPD Company Information
  57. 6.10.2 PPD Business Overview
  58. 6.10.3 PPD Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 PPD Preclinical Assets Product Portfolio
  60. 6.10.5 PPD Recent Developments
  61. 6.11 Crown Bioscience
  62. 6.11.1 Crown Bioscience Company Information
  63. 6.11.2 Crown Bioscience Business Overview
  64. 6.11.3 Crown Bioscience Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Crown Bioscience Preclinical Assets Product Portfolio
  66. 6.11.5 Crown Bioscience Recent Developments
  67. 6.12 Comparative Biosciences
  68. 6.12.1 Comparative Biosciences Company Information
  69. 6.12.2 Comparative Biosciences Business Overview
  70. 6.12.3 Comparative Biosciences Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Comparative Biosciences Preclinical Assets Product Portfolio
  72. 6.12.5 Comparative Biosciences Recent Developments
  73. 6.13 TCG Lifesciences
  74. 6.13.1 TCG Lifesciences Company Information
  75. 6.13.2 TCG Lifesciences Business Overview
  76. 6.13.3 TCG Lifesciences Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 TCG Lifesciences Preclinical Assets Product Portfolio
  78. 6.13.5 TCG Lifesciences Recent Developments
  79. 6.14 Domainex
  80. 6.14.1 Domainex Company Information
  81. 6.14.2 Domainex Business Overview
  82. 6.14.3 Domainex Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Domainex Preclinical Assets Product Portfolio
  84. 6.14.5 Domainex Recent Developments
  85. 6.15 Absorption Systems
  86. 6.15.1 Absorption Systems Company Information
  87. 6.15.2 Absorption Systems Business Overview
  88. 6.15.3 Absorption Systems Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Absorption Systems Preclinical Assets Product Portfolio
  90. 6.15.5 Absorption Systems Recent Developments
7 North America
  1. 7.1 North America Preclinical Assets Market Size (2021-2032)
  2. 7.2 North America Preclinical Assets Market Size by Type
  3. 7.2.1 North America Preclinical Assets Market Size by Type (2021-2026)
  4. 7.2.2 North America Preclinical Assets Market Size by Type (2027-2032)
  5. 7.2.3 North America Preclinical Assets Market Share by Type (2021-2032)
  6. 7.3 North America Preclinical Assets Market Size by Application
  7. 7.3.1 North America Preclinical Assets Market Size by Application (2021-2026)
  8. 7.3.2 North America Preclinical Assets Market Size by Application (2027-2032)
  9. 7.3.3 North America Preclinical Assets Market Share by Application (2021-2032)
  10. 7.4 North America Preclinical Assets Market Size by Country
  11. 7.4.1 North America Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Preclinical Assets Market Size by Country (2021-2026)
  13. 7.4.3 North America Preclinical Assets Market Size by Country (2027-2032)
  14. 7.4.4 North America Preclinical Assets Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Preclinical Assets Market Size (2021-2032)
  2. 8.2 Europe Preclinical Assets Market Size by Type
  3. 8.2.1 Europe Preclinical Assets Market Size by Type (2021-2026)
  4. 8.2.2 Europe Preclinical Assets Market Size by Type (2027-2032)
  5. 8.2.3 Europe Preclinical Assets Market Share by Type (2021-2032)
  6. 8.3 Europe Preclinical Assets Market Size by Application
  7. 8.3.1 Europe Preclinical Assets Market Size by Application (2021-2026)
  8. 8.3.2 Europe Preclinical Assets Market Size by Application (2027-2032)
  9. 8.3.3 Europe Preclinical Assets Market Share by Application (2021-2032)
  10. 8.4 Europe Preclinical Assets Market Size by Country
  11. 8.4.1 Europe Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Preclinical Assets Market Size by Country (2021-2026)
  13. 8.4.3 Europe Preclinical Assets Market Size by Country (2027-2032)
  14. 8.4.4 Europe Preclinical Assets Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Preclinical Assets Market Size (2021-2032)
  2. 9.2 China Preclinical Assets Market Size by Type
  3. 9.2.1 China Preclinical Assets Market Size by Type (2021-2026)
  4. 9.2.2 China Preclinical Assets Market Size by Type (2027-2032)
  5. 9.2.3 China Preclinical Assets Market Share by Type (2021-2032)
  6. 9.3 China Preclinical Assets Market Size by Application
  7. 9.3.1 China Preclinical Assets Market Size by Application (2021-2026)
  8. 9.3.2 China Preclinical Assets Market Size by Application (2027-2032)
  9. 9.3.3 China Preclinical Assets Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Preclinical Assets Market Size (2021-2032)
  2. 10.2 Asia Preclinical Assets Market Size by Type
  3. 10.2.1 Asia Preclinical Assets Market Size by Type (2021-2026)
  4. 10.2.2 Asia Preclinical Assets Market Size by Type (2027-2032)
  5. 10.2.3 Asia Preclinical Assets Market Share by Type (2021-2032)
  6. 10.3 Asia Preclinical Assets Market Size by Application
  7. 10.3.1 Asia Preclinical Assets Market Size by Application (2021-2026)
  8. 10.3.2 Asia Preclinical Assets Market Size by Application (2027-2032)
  9. 10.3.3 Asia Preclinical Assets Market Share by Application (2021-2032)
  10. 10.4 Asia Preclinical Assets Market Size by Country
  11. 10.4.1 Asia Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Preclinical Assets Market Size by Country (2021-2026)
  13. 10.4.3 Asia Preclinical Assets Market Size by Country (2027-2032)
  14. 10.4.4 Asia Preclinical Assets Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Preclinical Assets Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Preclinical Assets Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Preclinical Assets Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Preclinical Assets Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Preclinical Assets Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Preclinical Assets Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Preclinical Assets Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Preclinical Assets Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Preclinical Assets Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Preclinical Assets Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Preclinical Assets Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Preclinical Assets Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Preclinical Assets Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Preclinical Assets Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst